倍博特治疗轻中度老年原发性高血压的疗效及安全性观察  

Efficacy and safety of Exforge on elderly patients with mild-to-moderate essential hypertension

作　　者：殷泉忠[1] 崔俊友[1] 李健[1] 易桂斌[1] 陆叶[1] 陶金松[1] 郑若龙[1] 张华[1] 

机构地区：[1]东南大学医学院附属江阴医院心内科,江苏省无锡市214400

出　　处：《实用老年医学》2012年第5期371-373,共3页Practical Geriatrics

摘　　要：目的观察倍博特治疗轻中度老年原发性高血压的临床疗效及安全性。方法符合纳入标准的120例轻中度老年原发性高血压患者被随机分成3组:对照1组、对照2组和治疗组。对照1组患者给予80mg缬沙坦治疗;对照2组患者给予160mg缬沙坦治疗;治疗组患者给予倍博特(缬沙坦/氨氯地平:80mg/5mg);连续治疗12周,监测患者血压,比较治疗前后临床症状及体征变化。结果 6周和12周时,治疗组患者平均坐位舒张压(msDBP)和平均坐位收缩压(msSBP)下降值均明显优于对照1组(P<0.05),与对照2组相比,msDBP下降值仍占优势(P<0.05)。治疗组有效率为85.0%,明显高于对照组的47.5%和77.5%。治疗期间,3组患者均未出现严重不良反应。结论倍博特治疗轻中度老年原发性高血压呈现良好的临床效果。Objective To explore the efficacy and safety of Exforge on elderly patients with mild-to-moderate essential hypertension.Methods 120 essential hypertensive patients were randomly divided into 3 groups：control group 1,control group 2 and treatment group.The patients in control group 1 received 80 mg valsartan;control group 2 were given 160 mg valsartan;The patients in treatment group were administated with Exforge（valsartan/amlodipine：80 mg/5 mg）.The efficacy and safety were evaluated after treatment for 12 weeks.msDBP and msSBP of patients were determined and clinical symptoms and signs change were also observed before and after the treatment.Results After 6 and 12 weeks,the decline of msDBP and msSBP in treatment group were obviously more significant than those in control group 1,and the decline of msDBP were significantly greater than that in control group 2.In addition,the effective rate of treatment group（85.0%） was higher than those of control groups（47.5% and 77.5%,respectively）.No serious adverse events were observed during the treatment.Conclusions Exforge is effective on mild-to-moderate essential hypertensive patients and no side effects are identified.

关 键 词：倍博特 老年人 原发性高血压 缬沙坦 氨氯地平 

分 类 号：R743[医药卫生—神经病学与精神病学]